

# Flexible piecewise linear model for investigating dose-response relationship in meta-analysis: methodology, examples, and comparison

Chang Xu<sup>Corresp., 1</sup>, Lehana Thabane<sup>2</sup>, Tong-Zu Liu<sup>3</sup>, Ling Li<sup>1</sup>, Sayem Borhan<sup>2</sup>, Xin Sun<sup>Corresp., 1</sup>

<sup>1</sup> Chinese Evidence based medicine Center, West China Hospital, Chengdu, China

<sup>2</sup> Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada

<sup>3</sup> Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, China

Corresponding Authors: Chang Xu, Xin Sun

Email address: xuchang2016@runbox.com, sunx79@hotmail.com

**Objectives:** Dose-response meta-analysis (DRMA) is widely employed to establishing the potential dose-response relationship between continuous exposures and disease outcomes. However, no method is readily available for exploring the relation between a discrete exposure and a binary or continuous outcome. We proposed a piecewise linear (PL) DRMA model as a solution to this issue.

**Methods:** We illustrated the methodology of PL model in both one-stage DRMA approach and two-stage DRMA approach. The method by testing the equality of slopes of each piecewise was employed to judge if there is “piecewise effect” against simple linear trend. We then used sleep (continuous exposure) and parity (discrete exposure) data as examples to illustrate how to apply PL model in DRMA using the Stata code attached. We also empirically compared the slopes of PL model with simple linear as well as restricted cubic spline (RCS) model.

**Results:** Both one-stage and two-stage PL DRMA model fitted well in our examples, and the results were similar. Obvious “piecewise effects” were detected in both the two examples by the method we used. In our example, the PL model showed better fitting effect and practical reliable results compared to simple linear model, while similar results for to RCS model.

**Conclusion:** Piecewise linear function is a simple and valid method for DRMA and can be used for discrete exposures. It also represents a superior model to linear model in DRMA and may be an alternative model to non-linear model.

1 **Flexible piecewise linear model for investigating dose-response relationship in meta-**  
2 **analysis: methodology, examples, and comparison**

3 Chang Xu <sup>1</sup>, Lehana Thabane<sup>2</sup>, Tong-Zu Liu<sup>3</sup>, Ling Li<sup>1</sup>, ASM Borhan<sup>2</sup>, Xin Sun<sup>1\*</sup>

4

5 <sup>1</sup> Chinese Evidence-Based Medicine Center and Chinese Cochrane Center, West China Hospital,  
6 Sichuan University, Chengdu; Email: [xuchang2016@runbox.com](mailto:xuchang2016@runbox.com); [ebmliling@hotmail.com](mailto:ebmliling@hotmail.com);  
7 [sunx79@hotmail.com](mailto:sunx79@hotmail.com);

8 <sup>2</sup> Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280  
9 Main Street West, Hamilton, ON, L8S 4K1; Biostatistics Unit, Father Sean O'Sullivan Research  
10 Centre, St Joseph's Healthcare, 3rd Floor, Martha Wing, Room H-325, 50 Charlton Avenue East,  
11 Hamilton, ON, L8N 4A6, Canada; Email: [ThabanL@mcmaster.ca](mailto:ThabanL@mcmaster.ca); [borhana@mcmaster.ca](mailto:borhana@mcmaster.ca);

12 <sup>3</sup>Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan; Email:  
13 [liutongzu@163.com](mailto:liutongzu@163.com);

14

15 **Running title:** Piecewise linear model for dose-response meta-analysis

16

17 **\* Correspondence:**

18 Prof. Xin Sun, Chinese Evidence-based Medicine Center and CREAT Group, West China  
19 Hospital, Sichuan University, No.37 Guoxue Road, Wuhou district, Tel: +86 18980606047,  
20 Chengdu, China; Email: [sunx79@hotmail.com](mailto:sunx79@hotmail.com);

21

22

23

24 **Abstract**

25 **Objectives:** Dose-response meta-analysis (DRMA) is widely employed to establishing the  
26 potential dose-response relationship between continuous exposures and disease outcomes.  
27 However, no method is readily available for exploring the relation between a discrete exposure  
28 and a binary or continuous outcome. We proposed a piecewise linear (PL) DRMA model as a  
29 solution to this issue.

30 **Methods:** We illustrated the methodology of PL model in both one-stage DRMA approach and  
31 two-stage DRMA approach. The method by testing the equality of slopes of each piecewise was  
32 employed to judge if there is “piecewise effect” against simple linear trend. We then used sleep  
33 (continuous exposure) and parity (discrete exposure) data as examples to illustrate how to apply  
34 PL model in DRMA using the Stata code attached. We also empirically compared the slopes of  
35 PL model with simple linear as well as restricted cubic spline (RCS) model.

36 **Results:** Both one-stage and two-stage PL DRMA model fitted well in our examples, and the  
37 results were similar. Obvious “piecewise effects” were detected in both the two examples by the  
38 method we used. In our example, the PL model showed better fitting effect and practical reliable  
39 results compared to simple linear model, while similar results for to RCS model.

40 **Conclusion:** Piecewise linear function is a simple and valid method for DRMA and can be used  
41 for discrete exposures. It also represents a superior model to linear model in DRMA and may be  
42 an alternative model to non-linear model.

43

44 **Keywords** piecewise linear function, dose-response meta-analysis, discrete exposure

45

## 46 Introduction

47 In epidemiological research, one of the important tasks is the investigation of potential dose-  
48 response relationship between exposures and disease outcomes. In order to establish the evidence  
49 of dose-specific effects, dose-response meta-analysis (DRMA) may be used [1]. In recent years,  
50 DRMA has gained increasing attention and has been put in practice in evidence-based medicine.  
51 A survey has found that there were nearly 400 DRMAs were published by alone over the past  
52 five years, and the number continues increasing [2].

53 One critical methodological issue remains in DRMA is how to fit dose-specific effects. Both  
54 continuous and discrete variables may be used as the exposure in DRMA. Several regression  
55 methods have been developed for exploring relationship between continuous exposures and  
56 binary outcomes in DRMA, including the simple linear model [3], the natural quadratic model  
57 [4], the flexible polynomial model [5], and the restricted cubic spline model [6]. These models,  
58 covering both simple linear and non-linear trend approximation, have been proven to be valid.

59 However, no model is readily available for investigating dose-response relation for discrete  
60 exposures due to their nature of discontinuous. Some have used non-linear DRMA model to  
61 assess the relationship between discrete exposure and disease outcomes [7, 8]. Although their  
62 results tend to be correct, the method is questionable because discrete variable cannot be directly  
63 smooth as a curve (but can be line) between two specified points due to the disjoint nature and  
64 nonconvex property [9]. Simple linear model is an alternative. However, in many cases, simple  
65 linear model tend to be at risk of under fit and wrong prediction. For example, for J-shaped or U-  
66 shaped curves, simple linear model may lead to unrealistic conclusion since the slopes differ  
67 across piecewise [10].

68 In this article, we described piecewise linear (PL) model, which can be fitted in both one-stage  
69 and two-stage approach, to solve the problem. The model may represent a valid solution to  
70 establish dose-specific relation between discrete exposures and binary outcomes. In the  
71 following sections, we firstly describe the expression of PL function and the methodology of  
72 pooling interested estimators; we subsequently use the parity and sleep data for illustration of  
73 discrete and continuous variables and compare them with simple linear and nonlinear spline  
74 model; we finally offer an extension of the model and include our discussion. The main

75 command using for model implementation in Stata is presented in the supplementary file.

76

## 77 **Methods**

### 78 *Piecewise linear regression model*

79 A collection of  $j$  (1, 2, 3...,  $n$ ) is assumed as included studies and  $k$ (1, 2, 3...,  $i - 1$ ) as the knots  
80 assigned for the data distribution within a study. Then the data can be divided to  $i$  pieces. The  
81 expression of the model within each study can be written as

$$82 \quad \log Y = \alpha + \beta_i X + \varepsilon \quad (1)$$

83 Where  $\alpha$  is the intercept (not always needed),  $\beta_i$  are slopes or regression coefficients of  
84 assigned pieces (i) cut by knots.  $\varepsilon$  is the random error.  $Y$  is the relative risk of interested  
85 outcome, including odds ratio (OR), relative risk (RR), or hazard ratio (HR) [6]. A natural  
86 logarithm transformation is made to achieve an approximate normal distribution. For continuous  
87 outcomes,  $Y$  is the mean difference (MD) or the standard mean difference (SMD), and the log-  
88 transformation is not usually needed.  $X$  is the exposure, referring to continuous or discrete  
89 variables. If we insert one knot (50<sup>th</sup>) of the distribution of  $X$ , the slope would be divided into  
90 two pieces: 0~50<sup>th</sup> on the left side of the knot and 50<sup>th</sup>~100<sup>th</sup> on the right side. The integers  
91 should be chosen as cut points if  $X$  is a discrete variable. When  $\alpha$  equals zero (generally forced  
92 to be zero in binary outcome DRMA [6]), the expression (1) changes to

$$93 \quad \log Y = \beta_i X + \varepsilon \quad (2)$$

94 In such situation, the function is expected to go through the origin. The mathematical  
95 expectation of  $\log Y$  is the estimator of interested, as  $(\alpha + \beta_i X)$  in formula (1) and  $\beta_i X$  in  
96 formula (2). The key problem of the function is the estimation of  $\beta$ . Generally, ordinary least  
97 squares (OLS) estimation can reach the best linear unbiased evaluation (BLUE) for  $\beta$ . However,  
98 in meta-analysis of dose-response data, correlations between logRRs cannot be ignored. Orsini et  
99 al [13] proposed a generalized least square (GLS) method to satisfy BLUE property for  $\beta$  in  
100 DRMA. With the OLS method, the estimation of  $\beta$ ,  $\hat{\beta}_0$  could be estimated using the following  
101 formula:

$$102 \quad \hat{\beta}_0 = (X'X)^{-1}(X'Y) \quad (3)$$

103 While in the GLS method, the formula for estimation of  $\beta$ ,  $\hat{\beta}_G$  is

$$104 \quad \hat{\beta}_G = (X' C^{-1} X)^{-1} (X' C^{-1} Y) \quad (4)$$

105 Where  $C$  is the covariance matrix of  $Y$ , which generally needed to be estimated according to  
 106 group sizes information—that is, numbers of cases and controls/total of category levels within  
 107 each study [4]. When the group size information is missing, the GLS approach is hard to be  
 108 applied. An alternative way in this situation is to use the weighted least squares (WLS)  
 109 estimation [11]. Likewise, the WLS estimation of  $\beta$ ,  $\hat{\beta}_W$  could be conducted as below

$$110 \quad \hat{\beta}_W = (X' W^{-1} X)^{-1} (X' W^{-1} Y) \quad (5)$$

111  $W$  is the weight and is usually set as inverse variance in meta-analysis. The variance can be  
 112 generally written as

$$113 \quad \text{Var} = (X' \Omega^{-1} X)^{-1} \quad (6)$$

114 With  $\Omega$  indicates the identity matrix for OLS, covariance matrix for GLS, and weighted  
 115 variance matrix for WLS of  $Y$ .

116

### 117 *Synthesis methods of piecewise relationship*

118 Two methods are available to pool the regression estimators ( $\beta$ ), which refer to, the one-stage  
 119 approach and the two-stage approach. For the one-stage approach, all studies were treated as a  
 120 whole while each study was treated as a cluster [11]. This method was first described by Doi and  
 121 Chang [11], which based on WLS for the estimation and refers to random effect model, and  
 122 known as the robust-error meta-regression (REMR).. We did slight modification on it that forced  
 123 the intercept as zero in this model. Under the REMR model, the estimation of variance becomes:

$$124 \quad \text{Var} = (X' W X)^{-1} \left( \sum_{j=1}^n \sum_{i \in c_j} X' W \hat{\Sigma} W X \right) (X' W X)^{-1} \quad (7)$$

125 The synthesis of  $\beta$  in one-stage model is the actually the estimation of  $\beta$  of the regression due  
 126 to the nature of one-stage approach. Details were illustrated elsewhere [11].

127 The two-stage approach, which based on GLS, is first described by Orsini and known as  
 128 GLST [6]. It estimate the regression coefficients within each study first and then combine the  
 129 coefficients in fixed-, random-effect, or other weighting schemes. Let us assume one knot of the  
 130 function as illustration of two-stage method; consequently, we could obtain two piece of slopes (

131  $\beta_1$  and  $\beta_2$ ) in each study produced by the knot. Then formula

$$132 \begin{pmatrix} \beta_{1j} \\ \beta_{2j} \end{pmatrix} \sim N \left( \begin{pmatrix} \theta_1 \\ \theta_2 \end{pmatrix}, \Sigma + \Phi \right); \Sigma = \begin{pmatrix} \sigma_{1j}^2 & \sigma_1 \sigma_2 \rho_1 \\ \sigma_1 \sigma_2 \rho_1 & \sigma_{2j}^2 \end{pmatrix}; \Phi = \begin{pmatrix} \tau_1^2 & \tau_1 \tau_2 \rho_2 \\ \tau_1 \tau_2 \rho_2 & \tau_2^2 \end{pmatrix} \quad (8)$$

133 indicate the fixed- ( $\Phi = \mathbf{0}$ ) or random-effect model ( $\Phi \neq \mathbf{0}$ ) of the two-stage DRMA. Here  $\theta_1$   
 134 and  $\theta_2$  are the summarized estimators of  $\beta_{1j}$  and  $\beta_{2j}$ .  $\Sigma_j$  is the within-study variance matrix  
 135 while  $\Phi$  is the between-study variance matrix which need to be estimated.  $\rho_1$  and  $\rho_2$  are  
 136 correlation coefficients within  $\sigma$  ( $\sigma_{1j}$ ,  $\sigma_{2j}$ ) and  $\tau$  ( $\tau_1$ ,  $\tau_2$ ) respectively. Details of the algorithm  
 137 have been illustrated by White [12] and Matteo [5].

138

### 139 **Examples**

140 We used both the GLST approach (two-stage) and the REMR approach (one-stage) for PL  
 141 DRMA as examples. We tested the equality of the slopes (e.g.  $\beta_1$  and  $\beta_2$ ) of each piecewise as a  
 142 judgment of whether there is “piecewise effect” against the simple linear effect, and considered P  
 143  $< 0.1$  was statistical significance due to the lower power of the test. Random-effect model were  
 144 used due to the potential heterogeneity. All the analyses were illustrated in Stata/SE 14 (Stata  
 145 Corp, College Station, TX, USA). The code we used was presented in Table 1.

#### 146 ***Dose-response meta-analysis for continuous data***

147 In a large cohort-based dose-response meta-regression, Liu et al [13] has investigated the  
 148 relationship between sleep duration and all-cause mortality. We used their data as an example  
 149 but since we knew that sleep duration tends to have a grossly non-linear association with  
 150 mortality the dose needed to be centred but this time keeping the reference dose conceptually  
 151 constant. A look at the range of reference values for sleep duration revealed that in most cases  
 152 this was between 4.5 and 5.5 h with a mean of 5 h and thus we excluded all studies with a  
 153 reference of 6+ h (five studies). We also excluded a sixth study with an error that did not allow  
 154 computation of covariance required for the GLST model. Although the reference varied slightly  
 155 in the remaining studies, they were all assumed to have conceptually constant reference duration  
 156 of sleep at 5h. We centred by subtracting the actual reference dose from each non-reference dose

157 and thus modelled increments but considered all these increments to conceptually start from the  
158 5h sleep duration baseline.

159 Our meta-analysis showed that, based on GLST approach, significant “piecewise effect” was  
160 observed ( $P < 0.01$ ), the relative risk (RR) of all-cause mortality was 1.02 (95%CI: 1.00, 1.04)  
161 for every 1-hour reduction of sleep duration among people who slept less than 7 hours; the RR  
162 was 1.09 (95%CI: 1.09, 1.10) for every 1-hour increase of sleep duration among people who  
163 slept more than 7 hours (Figure 1a); based on REMR approach, the “piecewise effect” test was  
164 significant ( $P < 0.01$ ) and the RRs were 1.01 (95%CI: 1.01, 1.02) for each hour reduction when  
165 sleep less than 7 hours and 1.08 (95%CI: 1.05, 1.10) for each hour increase when sleep more  
166 than 7 hours, respectively (Figure 1b).

### 167 *Dose-response meta-analysis for discrete data*

168 Epidemiological studies suggested parity (number of birth) may relate to the risk of rheumatoid  
169 arthritis. We searched PubMed and Embase and crudely included 4 case-control or cohort studies  
170 about parity and risk of rheumatoid arthritis. We then used the parity data as an example of  
171 analyzing response of a discrete exposure with an outcome in DRMA (Table S2). We choose 3  
172 as the cut point of number of birth refers to evidence from previous similar publications [14, 15].  
173 This not need centered since all the studies with “doses” start from zero.

174 Our results showed that, based on GLST approach, for women with 3 or less births, the RR of  
175 rheumatoid arthritis was 0.94 (95%CI: 0.87, 1.01) for every 1-birth increment ( $P$  for “piecewise  
176 effect” was 0.03); for women with 3 or more births, the RR of rheumatoid arthritis was 1.13  
177 (95%CI: 1.01, 1.26) for every 1-birth increment (Figure 2a). Based on REMR approach, the RRs  
178 were 0.92 (95%CI: 0.83, 1.03) for every 1-birth increment for women with 3 or less births ( $P$  for  
179 “piecewise effect” was 0.06), and 1.15 (95%CI: 1.10, 1.32) for women with 3 or more births  
180 (Figure 2b).

## 181 **Results**

### 182 *Comparison to simple linear model*

183 A simple linear model was used to fit the dose-response relationship of the sleep duration and



184 all-cause mortality and compared it with the PL model. The results by simple linear model  
185 showed that RR for each-hour increment of sleep duration was 1.00 (95%CI: 0.97, 1.03) based  
186 on GLST approach and 0.99 (95%CI: 0.99, 1.00) based on REMR approach, respectively (Table  
187 2). Compared to PL model, these results obviously under fit and failed to in line with clinical  
188 practice.

### 189 *Comparison to non-linear spline model*

190 We used the restricted cubic spline (RCS) model [6] to fit a non-linear trend for sleep duration  
191 and all-cause mortality and compared it with the PL model. We insert 3 knots of the distribution  
192 of sleep duration in the RCS model. For non-linear relationship between sleep duration and risk  
193 of all-cause mortality, the slopes of PL model fitted well to RCS curve for both GLST and  
194 REMR approaches. The dose-specific results were similar for PL model and RCS model of the  
195 two approaches (Table 2).

196

### 197 **Discussion**

198 In this article, we proposed a new model for dose-response meta-analysis exploring relation  
199 between discrete variables and outcomes. To the best of our knowledge, few previous articles  
200 clearly address summarized dose-specific effects on discrete exposures. In our examples, this  
201 model fitted well and the results were reasonable. Our PL model is useful when non-linear  
202 association cannot be directly employed and linear association is not sufficient.

203 Previous models for DRMA have been well developed for continuous exposures, but are  
204 limited when discrete exposures are used. In practice, however, discrete variables are often used  
205 as exposures in DRMAs. While such types of exposure were usually misused. A cross-sectional  
206 study showed that 5.7% of published DRMAs inappropriately used discrete exposures to fit non-  
207 linear association [2]. This fact may result from the absence of usable model. Our model thus  
208 offers a solution for discrete exposures in DRMAs.

209 Generally, in a dose-response meta-analysis, the doses (e.g. 1-5 cup/day) were extracted from  
210 source publications and have to be changed into an acceptable form [6, 16]. Briefly, for closed

211 interval, the median or mean value of each exposure level is assigned to a corresponding relative  
212 risk [17]; for the open-ended interval (e.g. >5 cup/day), the assigned dose is estimated by  
213 multiplying 1.2 of cut-off point [18] or by assuming the range to be the same as the adjacent  
214 interval. However, these approaches are inappropriate for discrete variables because of which  
215 would result in decimals that are not allowed for discrete variables – the assigned doses for  
216 discrete variables are expected to be integer. Future studies are needed to focus this problem.

217 In DRMAs, it is important to decide a best-fit model among non-linear, piecewise linear, and  
218 simple linear procedures. For linear and non-linear association, the common approach often sets  
219 the coefficients of non-linear term as zero and test the probability of this null hypothesis. If  $P <$   
220  $0.1$  (assuming  $\alpha=0.1$ ), we have reasonable evidence to reject the null hypothesis and treat the  
221 potential trend as non-linear. A linear model would be chosen, otherwise. When non-linear  
222 association is not significant or cannot be directly used, it is reasonable to consider the piecewise  
223 or the simple linear model. We use the method of testing the equality of the slopes, which allows  
224 us to detect if there is “piecewise effect” against simple linear model. And the piecewise linear  
225 model should be chose when there is obvious “piecewise effect”.

226 In our examples, we presented the application of one-stage approach as were as the two-stage  
227 approach based on the PL model. We found that the results were mostly similar between one-  
228 stage and two-stage approach. One advantages of one-stage approach is it do not need the group  
229 size information of included studies while still allows a valid estimation; another advantages of  
230 one-stage approach is the exempt assumption of normal distribution of the regression coefficients.  
231 While for two-stage approach allows for the estimation of heterogeneity between studies and  
232 correlation between regression coefficients. Both these two approaches can be easily applied by  
233 the STATA code we attached.

234 The proposed method has a few limitations. First, the piecewise linear model is a special type  
235 of linear function; the results are less precise and flexible compared to higher order function (e.g.  
236 third order). Although adding more knots may improve precision, the results remain to be at risk  
237 of under fit when a non-linear association is significant. Second, inverse variance or other  
238 weighting schemes according to sample sizes were used in current methods; such methods,  
239 however, do not address the issue of study quality. Suhail A.R et al [19] proposed a quality effect

240 (QE) model that included study quality for adjusting pooled effect estimates from meta-analysis  
241 of observational studies may serve as a potential solution. Third, a valid approach to determining  
242 the best cut point of the distribution of exposure has yet to be established, although adjusted R-  
243 squared may offer some suggestions.

244 In conclusion, piecewise linear function is a simple and valid method for DRMA. It is useful  
245 for assessing relation between discrete exposures and outcomes, and represents an alternative  
246 model to the non-linear model, and it may also be a superior model to linear model in DRMA.  
247 Further studies should focus on improving the precision of cut point selection as well as the  
248 flexibility of PL model.

249

250 **Conflicts of interests**

251 None.

252 **Funding**

253 None.

254 **Acknowledgments:** We thank Dr. Ji Liang from ZunYi Medical University for searching and  
255 providing us the parity data.

256 **Author Contributions:** Proposed the method: Chang Xu; Data analysis: Chang Xu; Draft the  
257 manuscript: Chang Xu; Revise the manuscript: Xin Sun, Lehana Thabane.

258 **Data Sharing Statement:** All the data we used were shared in the supplementary file.

259

260 **Reference**

- 261 1. Bagnardi V, Zambon A, Quatto P, et al. Flexible meta-regression functions for modeling  
262 aggregate dose–response data, with an application to alcohol and mortality. *American*  
263 *Journal of Epidemiology* 2004; 159(11): 1077–1086.
- 264 2. Xu C, Doi SA, Zhang C, et al. Proposed Reporting Guidelines for dose-response Meta-  
265 analysis (Chinese Edition). *Chinese journal of evidence-based medicine* 2016; 16(10): 1221-  
266 1226.
- 267 3. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose–  
268 response data, with applications to meta-analysis. *American Journal of Epidemiology* 1992;  
269 135(11): 1301–1309.
- 270 4. Liu Q, Cook NR, Bergström A, et al. A two-stage hierarchical regression model for meta-  
271 analysis of epidemiologic nonlinear dose–response data. *Comput Stat Data An* 2009; 53(12):  
272 4157-4167.
- 273 5. Rota M, Bellocco R, Scotti L, et al. Random-effects meta-regression models for studying  
274 nonlinear dose–response relationship, with an application to alcohol and esophageal  
275 squamous cell carcinoma. *Statistics in Medicine* 2010; 29(26): 2679–2687.
- 276 6. Orsini N, Li R, Wolk A, et al. Meta-analysis for linear and nonlinear dose–response relations:  
277 examples, an evaluation of approximations, and software. *American Journal of*  
278 *Epidemiology* 2012; (175): 66–73.
- 279 7. Guo P, Xu C, Zhou Q, et al. Number of parity and the risk of gallbladder cancer: a  
280 systematic review and dose-response meta-analysis of observational studies. *Arch Gynecol*  
281 *Obstet* 2016; 293(5): 1087-96.
- 282 8. Rong Y, Chen L, Zhu T, et al. Egg consumption and risk of coronary heart disease and  
283 stroke: dose-response meta-analysis of prospective cohort studies. *BMJ* 2013; 346:e8539.
- 284 9. Arora JS, Huang MW, Hsieh CC. Methods for optimization of nonlinear problems with  
285 discrete variables: A review. *Structural Optimization* 1994; 8: 69.
- 286 10. Zhang C, Jia P, Yu L, et al. Introduction to methodology of dose-response meta-analysis for  
287 binary outcome: With application on software. *J Evid Based Med* 2018. doi:  
288 10.1111/jebm.12267.
- 289 11. Xu C, Doi SA. The robust-error meta-regression method for dose-response meta-analysis.  
290 *International Journal of Evidence-Based Healthcare* 2018; 16(3):138-144.

- 291 12. White IR. Multivariate random-effects meta-regression: Updates to mvmeta. *Stata Journal*  
292 2011; 11(2): 255-270.
- 293 13. Liu TZ, Xu C, Matteo R, et al. Sleep duration and risk of all-cause mortality: A flexible non-  
294 linear meta-regression of 40 prospective cohort studies. *Sleep Medicine Reviews* 2017;  
295 32:28-36.
- 296 14. Konishi S, Ng CFS, Watanabe C. U-shaped association between fertility and mortality in a  
297 community-based sample of Japanese women. *J Epidemiol Community Health* 2018. pii:  
298 jech-2017-209809. doi: 10.1136/jech-2017-209809.
- 299 15. Sung HK, Ma SH1, Choi JY, et al. The Effect of Breastfeeding Duration and Parity on the  
300 Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis. *J Prev Med*  
301 *Public Health* 2016; 49(6):349-366.
- 302 16. Hamling J, Lee P, Weitkunat R, et al. Facilitating meta-analyses by deriving relative effect  
303 and precision estimates for alternative comparisons from a set of estimates presented by  
304 exposure level or disease category. *Stat Med* 2008; 27(7): 954-70.
- 305 17. Bekkering GE, Harris RJ, Thomas S, et al. How much of the data published in observational  
306 studies of the association between diet and prostate or bladder cancer is usable for meta-  
307 analysis? *Am J Epidemiol* 2008; 167(9): 1017-26.
- 308 18. Xu C, Zeng XT, Liu TZ, et al. Fruits and Vegetables Intake and Risk of Bladder Cancer: A  
309 PRISMA-Compliant Systematic Review and Dose-Response Meta-Analysis of Prospective  
310 Cohort Studies. *Medicine (Baltimore)* 2015; 94(17): e759.
- 311 19. Doi SA, Barendregt JJ, Khan S, et al. Advances in the meta-analysis of heterogeneous  
312 clinical trials II: The quality effects model. *Contemp Clin Trials* 2015; 45(Pt A): 123-9.
- 313

314 **Figure legends**

315 **Figure 1.** Piecewise linear prediction for sleep duration and risk of all-cause mortality: a) based  
316 on random-effect GLST approach ( $P < 0.01$  for “piecewise effect” test); b) based on REMR  
317 approach ( $P < 0.01$  for “piecewise effect” test).

318 **Figure 2.** Piecewise linear prediction for parity and risk of rheumatoid arthritis: a) based on  
319 random-effect GLST approach ( $P = 0.03$  for “piecewise effect” test); b) based on REMR  
320 approach ( $P = 0.06$  for “piecewise effect” test).

321

322

**Figure 1** (on next page)

Figure 1

**Figure 1.** Piecewise linear prediction for sleep duration and risk of all-cause mortality:

a) based on random-effect GLST approach ( $P < 0.01$  for “piecewise effect” test);

b) based on REMR approach ( $P < 0.01$  for “piecewise effect” test).






Figure 1a. Sleep duration, hours/day




Figure 1b. Sleep duration, hours/day

**Figure 2** (on next page)

Figure 2

**Figure 2.** Piecewise linear prediction for parity and risk of rheumatoid arthritis: a) based on random-effect GLST approach ( $P = 0.03$  for “piecewise effect” test); b) based on REMR approach ( $P = 0.06$  for “piecewise effect” test)




Figure 2a.Number of birth




Figure 2b.Number of birth


**Table 1** (on next page)

Table 1

**Table 1.** Stata commands for piecewise linear DRMA for sleep data.

1 **Table 1.** Stata commands for piecewise linear DRMA for sleep data.

<p><b><i>GLST approach-random effect</i></b></p> <p><b><i>***Data centering(if needed)</i></b></p> <p><i>bysort id: gen dosec =(dose- dose[1])+5</i></p> <p><b><i>*** Weighting</i></b></p> <p><i>gen wt=1/(se^2)</i></p> <p><b><i>***Regression</i></b></p> <p><i>mkspline linsp_dose1 7 linsp_dose2 = dosec,</i> <i>marginal displayknots</i></p> <p><i>glst logrr linsp_dose*, cov(n case) se(se)</i></p> <p><i>pfirst(id studytype) r eform</i></p> <p><b><i>***test for piecewise effect</i></b></p> <p><i>test linsp_dose1= linsp_dose2</i></p> <p><b><i>***Get linear results of each pieces</i></b></p> <p><i>lincom linsp_dose1*-1, eform</i></p> <p><i>lincom linsp_dose2*1, eform</i></p> <p><b><i>***Dose-specific results and plots</i></b></p> <p><i>quietly levelsof dosec, local(levels)</i></p> <p><i>xblc linsp_dose* , covname (dosec) at(`r(levels)')</i></p> <p><i>ref (7) eform line</i></p>	<p><b><i>REMR approach without intercept</i></b></p> <p><b><i>***Data centering(if needed)</i></b></p> <p><i>bysort id: gen dosec =(dose- dose[1])+5</i></p> <p><b><i>***Weighting</i></b></p> <p><i>gen wt=1/(se^2)</i></p> <p><i>bysort id: egen maxwt=max(wt)</i></p> <p><i>replace wt = maxwt if wt==.</i></p> <p><b><i>***Regression</i></b></p> <p><i>mkspline linsp_dose1 7 linsp_dose2 = dosec,</i> <i>marginal displayknots</i></p> <p><i>regress logrr linsp_dose* [aweight=wt], nocons</i> <i>vce(cluster author) eform (exp beta)</i></p> <p><b><i>***test for piecewise effect</i></b></p> <p><i>test linsp_dose1 =linsp_dose2</i></p> <p><b><i>***Get linear results of each pieces</i></b></p> <p><i>lincom linsp_dose1*-1, eform</i></p> <p><i>lincom linsp_dose2*1, eform</i></p> <p><b><i>***Dose-specific results and plots</i></b></p> <p><i>quietly levelsof dosec, local(levels)</i></p> <p><i>xblc linsp_dose* , covname (dosec) at(`r(levels)')</i></p> <p><i>ref (7) eform line</i></p>
--	--



2

3

**Table 2** (on next page)

Table 2

**Table 2.** Comparison between piecewise linear and linear as well as cubic spline model.

1 **Table 2.** Comparison between piecewise linear and linear as well as cubic spline model.

<b>Examples</b>	<b>GLST</b>		<b>REMR</b>	
	<i>Piecewise linear</i>	<i>Simple linear</i>	<i>Piecewise linear</i>	<i>Simple linear</i>
<i>Sleep duration</i>				
<7, 1-hour decrease	1.02 (1.004, 1.04)	—	1.01 (1.01, 1.02)	—
>=7, 1-hour increase	1.09 (1.09, 1.10)	—	1.08 (1.05, 1.10)	—
1-hour increase	—	1.00 (0.97, 1.03)	—	0.99 (0.99, 1.00)
<i>Sleep duration(continuous)</i>	<i>Piecewise linear</i>	<i>Cubic spline</i>	<i>Piecewise linear</i>	<i>Cubic spline</i>
5 h	1.04 (1.01-1.07)	1.01 (0.99-1.04)	1.04 (1.03-1.05)	1.01 (1.00-1.02)
6 h	1.02 (1.00-1.03)	0.99 (0.98-1.01)	1.02 (1.02-1.02)	0.99 (0.99-1.00)
7 h	Reference	Reference	Reference	Reference
8 h	1.08 (1.06-1.09)	1.05 (1.03-1.06)	1.08 (1.06-1.10)	1.05 (1.03-1.06)
9 h	1.16 (1.12-1.20)	1.14 (1.10-1.17)	1.17 (1.12-1.22)	1.13 (1.09-1.17)

2